ValuEngine cut shares of Galectin Therapeutics Inc. (NASDAQ:GALT) from a hold rating to a sell rating in a report released on Tuesday, August 1st.
Other analysts also recently issued reports about the stock. Zacks Investment Research raised shares of Galectin Therapeutics from a hold rating to a buy rating and set a $2.50 price target for the company in a research note on Wednesday, April 5th. FBR & Co reissued a market perform rating and issued a $2.00 price target on shares of Galectin Therapeutics in a research note on Monday, April 3rd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. Galectin Therapeutics currently has a consensus rating of Hold and a consensus price target of $2.25.
Galectin Therapeutics (GALT) traded down 4.97% during mid-day trading on Tuesday, reaching $1.72. The company had a trading volume of 174,200 shares. Galectin Therapeutics has a 12-month low of $0.49 and a 12-month high of $3.68. The firm has a 50-day moving average price of $2.22 and a 200 day moving average price of $2.21. The firm’s market capitalization is $59.63 million.
Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings results on Monday, May 15th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.01. Analysts expect that Galectin Therapeutics will post ($0.56) EPS for the current year.
Hedge funds have recently bought and sold shares of the company. Buckingham Asset Management LLC acquired a new stake in Galectin Therapeutics during the first quarter valued at $115,000. Cutter & CO Brokerage Inc. boosted its position in Galectin Therapeutics by 57.2% in the first quarter. Cutter & CO Brokerage Inc. now owns 56,600 shares of the company’s stock worth $130,000 after buying an additional 20,600 shares during the last quarter. Northern Trust Corp boosted its position in Galectin Therapeutics by 4.4% in the second quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock worth $185,000 after buying an additional 3,176 shares during the last quarter. KCG Holdings Inc. boosted its position in Galectin Therapeutics by 1.9% in the first quarter. KCG Holdings Inc. now owns 86,195 shares of the company’s stock worth $198,000 after buying an additional 1,592 shares during the last quarter. Finally, Virtu KCG Holdings LLC boosted its position in Galectin Therapeutics by 24.4% in the second quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock worth $264,000 after buying an additional 21,008 shares during the last quarter. 11.39% of the stock is owned by institutional investors and hedge funds.
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.